Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome

Gal Dinstag,Eldad D Shulman,Efrat Elis,Doreen S Ben-Zvi,Omer Tirosh,Eden Maimon,Isaac Meilijson,Emmanuel Elalouf,Boris Temkin,Philipp Vitkovsky,Eyal Schiff,Danh-Tai Hoang,Sanju Sinha,Nishanth Ulhas Nair,Joo Sang Lee,Alejandro A Schäffer,Ze'ev Ronai,Dejan Juric,Andrea B Apolo,William L Dahut,Stanley Lipkowitz,Raanan Berger,Razelle Kurzrock,Antonios Papanicolau-Sengos,Fatima Karzai,Mark R Gilbert,Kenneth Aldape,Padma S Rajagopal,Tuvik Beker,Eytan Ruppin,Ranit Aharonov

DOI: https://doi.org/10.1016/j.medj.2022.11.001

2023-01-13

Med

Abstract:Background: Precision oncology is gradually advancing into mainstream clinical practice, demonstrating significant survival benefits. However, eligibility and response rates remain limited in many cases, calling for better predictive biomarkers. Methods: We present ENLIGHT, a transcriptomics-based computational approach that identifies clinically relevant genetic interactions and uses them to predict a patient's response to a variety of therapies in multiple cancer types without training on previous treatment response data. We study ENLIGHT in two translationally oriented scenarios: personalized oncology (PO), aimed at prioritizing treatments for a single patient, and clinical trial design (CTD), selecting the most likely responders in a patient cohort. Findings: Evaluating ENLIGHT's performance on 21 blinded clinical trial datasets in the PO setting, we show that it can effectively predict a patient's treatment response across multiple therapies and cancer types. Its prediction accuracy is better than previously published transcriptomics-based signatures and is comparable with that of supervised predictors developed for specific indications and drugs. In combination with the interferon-γ signature, ENLIGHT achieves an odds ratio larger than 4 in predicting response to immune checkpoint therapy. In the CTD scenario, ENLIGHT can potentially enhance clinical trial success for immunotherapies and other monoclonal antibodies by excluding non-responders while overall achieving more than 90% of the response rate attainable under an optimal exclusion strategy. Conclusions: ENLIGHT demonstrably enhances the ability to predict therapeutic response across multiple cancer types from the bulk tumor transcriptome. Funding: This research was supported in part by the Intramural Research Program, NIH and by the Israeli Innovation Authority.